Therefore, we examined whether the presence of mammary carcinomas affects the development and deployment of CD45–CD117/c-Kit+Flk1/Vegfr2+ EPCs and whether CCL2 and CCR2 play a role. This evidence concerns the gene CCR2 and breast carcinoma.